Point of care testing evaluation of lateral flow immunoassay for diagnosis of cryptococcus meningitis in HIV-positive patients at an urban hospital in Nairobi, Kenya, 2017

Lawrence Kirimi Gitonga1,2,3, Waqo Gufu Boru1,3, Arthur Kwena2, Marybeth Maritim5, Joyce Wamicwe3,4 and James Ransom1,6*

Abstract

Objectives: The objective of this study was to evaluate the performance of lateral flow immunoassay (LFA) against
latex agglutination (LA), India ink and culture in point-of-care diagnosis of cryptococcus meningitis (CM). We con-
ducted cross-sectional study among HIV-positive patients with suspected CM at Mbagathi Hospital, Nairobi, April–July
2017.

Results: Of 124 capillary blood and serum and 99 cerebrospinal fluid (CSF) samples, LFA and LA had a concurrence
on serum of 94.4%, kappa (0.88), sensitivity (100%) and specificity (91%). LFA and LA on CSF, was 97.9%, kappa (0.96),
sensitivity (100%) and specificity (96%). LFA and India ink was 96.9%, kappa (0.94), sensitivity (100%) and specificity
(94.1%). On CSF culture, concurrence was 72.7%, kappa (0.43), sensitivity (100%) and specificity (64%) and of LFA on
capillary blood, serum and CSF was 100% with kappa (1.00), sensitivity and specificity of 100%.

Keywords: Point of care, Meningitis, Kenya, HIV

Introduction

Cryptococcus meningitis (CM) is a life-threatening opportunistic infection among HIV-infected persons
[1]. In Africa, CM is the second leading cause of death in HIV-infected persons [2], with a case fatality rate (CFR)
of up to 38% among outpatients and 81–100% among inpatients [3]. In Kenya, up to 33% of people with AIDS
develop CM [4]. CM diagnosis usually occurs when meningitis is at an advanced stage and treatment is less effec-
tive [1, 5, 6].

Culture is the gold standard diagnostic method for CM, but it has poor sensitivity, requires approximately
100 µl of cerebral spinal fluid (CSF), technical expertise, and laboratory infrastructure [7, 8]. Microscopy requires
laboratory infrastructure, and latex agglutination (LA) has sensitivity and specificity of > 99% and is less labour
intensive than culture but also requires technical expertise and laboratory infrastructure. Culture and LA are
not available in resource constrained settings, thus limiting their clinical utility [9].

Lateral flow immunoassay (LFA) is a point-of-care (POC) qualitative test to detect capsular polysaccharide
antigens of Cryptococcus species complex (Cryptococcus neoformans and Cryptococcus gattii) [9–11]. LFA can use
whole blood, serum, or CSF, is room temperature stable, has a rapid turnaround time of < 15 min, is simple to per-
form, and can be interpreted by personnel with minimal training [9].

Most studies evaluating LFA are focused on use of serum and CSF [7, 8, 12–14]. There are few data on use

*Correspondence: james.ransom@piretpartners.com
6 Piret Partners Consulting, Washington, DC, USA
Full list of author information is available at the end of the article
of LFA on capillary blood [15] or evaluation of LFA in Kenya. This study aimed to determine the agreement of test results from LFA on capillary blood, serum and CSF with those from LA on serum, CSF, India ink microscopy and culture on CSF.

Main text

Methods

Study design
We conducted a hospital-based cross-sectional study from April to July 2017.

Study site and population
The study was conducted at Mbagathi Hospital, a referral facility located in Nairobi County. The evaluation targeted patients ≥ 18 years scheduled for lumbar puncture (LP) and routine blood sample collection for CM diagnosis.

Inclusion criteria
LP requested by health care provider, availability of remnant serum and CSF (≥ 500 µl) after routine Cryptococcus LA or culture was performed on HIV-positive patients ≥ 18 years with the ability and willingness to provide informed consent.

Exclusion criteria
Patients involuntarily incarcerated in the hospital for psychiatric or physical illness, any patient/patient with a guardian who was deemed mentally unstable or unable to provide informed consent. Patients on any antifungal treatment and patients who were having repeat LPs.

Sample size assumptions and calculation
The sample size of 125 participants was calculated using Fisher’s formulae, assuming the expected proportion of agreement between LFA and other methodologies (p) was 97.7% and the precision (P) of 3% [16].

Sampling methods
We reviewed records for 6 months at Mbagathi Hospital and obtained an average of 95 cases of suspected CM in a month. To achieve a sample size of 125 patients using the estimated sampling frame of 285 within a period of 3 months, every second HIV-positive patient ≥ 18 years suspected of CM and scheduled for routine LP and blood collection for CM diagnosis was enrolled after giving written consent to obtain an additional capillary blood and use of the remnant CSF and serum for evaluation of LFA.

Data collection
The attending laboratory technologist collected blood samples from patients as part of routine testing requested by the clinician. Serum was centrifuged and separated for LA and LFA assays. CSF samples were collected by LP and centrifuged. The supernatant was used for LFA and LA assays and the pellet for culture. Sera were tested by LA, and CSF (where available) was tested by India ink microscopy and culture for clinical management of the patient. Leftover sera and CSF samples were used for the laboratory evaluation. A minimum of 500 µl of the remaining sample was aliquoted into 1.8 ml cryogenic vials. The samples were stored at 4 °C for a maximum of 72 h or at −20 °C awaiting transportation to the Central Microbiology Reference Laboratory (CMRL). Additionally, a non-routine finger prick capillary blood sample was requested from all enrolled patients. Using standardized lancets and micro capillary tubes, ~ 50 µl of blood was transferred into micro centrifuge tubes containing LFA specimen diluent. The test was performed at the sample collection site per manufacturer instructions. Sera and CSF sample processing were done at CMRL per laboratory standard operating procedures and manufacturer instructions (Fig. 1).

Data management and analysis
Data on the test type and test results in different sample types were entered and cleaned in MS-Excel version 2013. Statistics were calculated using GraphPad QuickCalcs 2017 (GraphPad Software, Inc., La Jolla, CA) with categorical data analysis to assess sensitivity, specificity, predictive values, confidence intervals (CIs) of proportion, overall percent agreement, and kappa (k) coefficients of India ink, LA, LFA and culture in sera, CSF and capillary blood. Interpretation of k was per standard guidelines [17].

Results
Figure 2 outlines the results of the comparison studies. Out of 128 persons suspected of CM, 124 were enrolled in the study. A total of 124 capillary blood and serum samples, and 99 CSF samples, were analysed. Twenty-five patients were not able to yield CSF sample. Comparing LFA to LA on sera, the sensitivity and specificity were 100% (95% CI 92.3–100) and 91% (95% CI 82.6–95.6) respectively, PPV and NPV at 86.8% and 100% with a total agreement of 94.4%, and a kappa of 0.88 (95% CI 0.80–0.97). LFA to LA on CSF, the sensitivity and specificity were 100% (95% CI 92.7–100) and 96% (95% CI 86.5–98.9), PPV and NPV at 96.1 and 100
with a total agreement of 98% and a kappa-value of 0.96 (95% CI 0.90–1.00).

Comparison of LFA to India ink (microscopy) using CSF, the sensitivity and specificity were 100% (95% CI 92.6–100) and 94.1% (95% CI 84.1–97.9), PPV and NPV at 94.1% and 100% with a total agreement of 97% and a kappa-value of 0.94 (95% CI 0.87–1.00). On comparison of LFA to culture on CSF, the sensitivity and specificity were 100% (95% CI 86.2–100) and 64% (95% CI 52.7–73.9), PPV and NPV at 47.6% and 100% with a total agreement of 72.7% and a kappa-value of 0.46 (95% CI 0.32–0.61).

Comparison of culture to LA using CSF, the sensitivity and specificity were 95.8 (95% CI 79.8–99.3) and 65.3 (95% CI 54.1–75.1) with a total agreement of 72% and a kappa value of 0.45 (95% CI 0.30–0.60). On comparison to India ink, the sensitivity and specificity were 95.9% (95% CI 79.8–99.3) and 66.7% (95% CI 55.4–76.3) with a total agreement of 73% and a kappa value of 0.47 (95% CI 0.31–0.62).

Comparison of LFA on capillary blood to LFA on sera, the sensitivity and specificity were 100%, PPV and NPV with a total agreement of 100%, and a kappa-value of 1.00 (95% CI 1.00–1.00). LFA on capillary blood was
compared to LFA on CSF, the sensitivity, specificity and predictive values were all 100% with a total agreement of 100% and a kappa-value of 1.00 (95% CI 1.00–1.00).

Conclusion and recommendation

Conclusion

Our results show high agreement between LFA, LA and India ink in different samples and a perfect agreement between LFA in different samples. The high agreement shows that LFA is a reliable POC diagnostic test. The results on individual tests show that there was almost perfect agreement between LFA and LA on CSF and serum. The test demonstrated high level of sensitivity and specificity of LFA compared to LA on sera and CSF. The findings from comparison of LFA to India ink microscopy using CSF demonstrated high sensitivity, specificity, and predictive values. This is in contrast to the findings from the expert opinion and other studies that documented lower sensitivity and NPV for CSF microscopy against LFA [7, 9]. The India ink microscopy requires laboratory infrastructure, dependent on fungal concentration and is highly operator dependent rather than the test performance.

On comparison of LFA to culture using CSF, there was high sensitivity, low specificity, and moderate agreement with a weak kappa value. The findings were consistent with other studies that documented high sensitivity and low specificity [14, 19]. The findings on high sensitivity, low specificity and a weak kappa value were similarly demonstrated when CSF culture was compared to LA
and India ink using CSF. However, other studies documented low sensitivity in CSF culture when compared against other diagnostic tests [7–9].

LFA on capillary blood was compared with LFA on serum and CSF. The LFA results on capillary blood had an ideal concordance with LFA serum and CSF results. LFA had a very high positive and negative predictive values both on serum and CSF, a characteristic that makes it good for an accurate diagnosis of cryptococcal meningitis. The high sensitivity and specificity of the test and its ability to be easily performed at the bedside and giving accurate results rapidly allows for prompt and timely initiation of treatment [9]. The findings were comparable with a similar study on evaluation of LFA using serum, CSF and capillary blood in Uganda [15, 18, 20].

**Recommendation**

The evidence of the perfect agreement between LFA on capillary blood, serum and CSF, high sensitivity and specificity, ease of performance, along with rapid results may indicate LFA using capillary blood POC test as the method of choice for CM diagnosis. Our results show that LFA meets World Health Organization assured criteria for POC diagnostic tests in resource-limited settings. Therefore, we recommend use of LFA test as a POC test in resource limited settings for the diagnosis of CM.

**Limitation of the study**

The limitations of this study include participants not yielding CSF sample due to dry taps, thus reducing the CSF samples that were analysed. The difference on CSF samples analysed had no major implications to the overall evaluation since there were more than one sample type used in the evaluation. Capillary blood could only be used on LFA test thus, there was no uniform use of the sample type across other testing procedures.

**Abbreviations**

AFENET: African Field Epidemiology Network; CFR: case fatality rate; CI: confidence interval; CM: cryptococcal meningitis; CMRL: Central Microbiology Reference Lab; CSF: cerebrospinal fluid; LA: latex agglutination; LFA: lateral flow immunoassay; LP: lumbar puncture; NPV: negative predictive value; POC: point of care; PPV: positive predictive value.

**Acknowledgements**

We acknowledge the administration of Mbagathi Hospital, Peter Kinyanjui, and James Mwangi for their helpful technical assistance.

**Authors’ contributions**

LKG conceptualized the study. WGB, AK, MM, JR, and JW contributed to the development of the study and the evaluation process. LKG conducted the data collection, analysis and drafted the manuscript. All the authors revised the manuscript and agreed with the manuscript content. All authors read and approved the final manuscript.

**Funding**

Financial support for this research was provided by Africa Field Epidemiology Network (AFENET). AFENET had no role in design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

**Availability of data and materials**

All data related to this study are available upon request.

**Ethics approval and consent to participate**

Written informed consent was obtained from all participants to allow an additional non-routine capillary blood sample and to have their remnant sample used for evaluating new diagnostics for CM. Permission to conduct this evaluation was approved by the Ethical Review Board of Moi University (FAN: IREC 1795), and Research Committee, Mbagathi Hospital.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Field Epidemiology and Laboratory Training Program, Nairobi, Kenya. 2. Moi University, Eldoret, Kenya. 3. Ministry of Health, Nairobi, Kenya. 4. National AIDS and STI Control Program-Ministry of Health, Nairobi, Kenya. 5. University of Nairobi, Nairobi, Kenya. 6. Piret Partners Consulting, Washington, DC, USA.

**Received: 18 September 2019 Accepted: 27 November 2019 Published online: 05 December 2019**

**References**

1. Kanji SS, Kakai R, Onyango RO. Cryptococcal meningitis among human immunodeficiency virus patients attending major hospitals in Kisumu, Western Kenya. Arch Clin Microbiol. 2011;2(1):1–6.

2. Park BJ, Wannemuehler KA, Marston BJ, Jaoko W, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(4):525–30. http://content.wkhealth.com/linkback/openurl?sid=WKPTPLandingPage&an=0002030-20090200-00012.

3. Kendi C, J. Penner, J. Koech, M. Nyonda, E. Bukusi, C. Cohen, H. Mutai AM. Case fatality due to cryptococcal meningitis in a retrospective cohort in Kenya. In: In AIDS 2010—XVII International AIDS Conference: Abstract no MOPE0115. 2010.

4. Mdoço R, Brown K, Omonge E, Jaoko W, Baddley J. Outcome associated with cryptococcal meningitis. East Afr Med J. 2013;87(12):481–7.

5. Sloan DJ, Parris V. Cryptococcal meningitis: epidemiology and therapeutic options. Clin Epidemiol. 2014;6(1):169–82.

6. Tenforde MW, Wake B, Leeme T, Jarvis JN. HIV-associated cryptococcal meningitis: bridging the gap between developed and resource-limited settings. Curr Clin Microbiol Rep. 2016;3(2):92–102. https://doi.org/10.1007/s40588-016-0035-5.

7. Boulware DR, Rolles MA, Rajasingham R, von Hohenberg M, Qin Z, Tauxe R, et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis. 2014;20(1):45–53.

8. Lindsley MD, Mehra N, Baggott HC, Surinthong Y, Autschheimai R, Sawatwong P, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis. 2011;53(4):321–5.

9. Koziel T, Bauman S. CrAg lateral flow assay for cryptococcosis. Expert Opin Med Diagn. 2013;6(3):775–84.

10. Hansen J, Slecha ES, Gates-Hollingsworth MA, Neary B, Barker AP, Baum L, et al. Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid. Clin Vaccine Immunol. 2013;20(1):52–5.

11. Koczula KM, Gallotta A. Lateral flow assays. Essays Biochem. 2016;60:111–20.
12. Binnicker MJ, Jespersen DJ, Bestrom JE, Rollins LO. Comparison of four assays for the detection of cryptococcal antigen. Clin Vaccine Immunol. 2012;19(12):1968–90.
13. Huang H, Fan L, Rajbanshi B, Xu J. Evaluation of a new cryptococcal antigen lateral flow immunoassay in serum, cerebrospinal fluid and urine for the diagnosis of cryptococcosis: a meta-analysis and systematic review. PLoS ONE. 2015;7(8):1–10.
14. Jin R, Cyto B, Med M, Wamachi A, Med D, Med HND, et al. Evaluation of rapid diagnostic methods for the diagnosis of cryptococcal meningitis in HIV positive patients in a health facility, Nairobi-Kenya. East Afr J Pathol. 2015;2:18–22.
15. Williams DA, Kizza T, Kwizera R, Kiggundu R, Velamakanni S, Meya DR, et al. Evaluation of Fingerstick cryptococcal antigen lateral flow assay in HIV-infected persons: a diagnostic accuracy study. Clin Infect Dis. 2015;61(3):464–7.
16. Cochran WG. Sampling techniques. New York: Wiley; 1977. p. 428.
17. Flight L, Julious SA. The disagreeable behaviour of the kappa statistic. Pharm Stat. 2015;14(1):74–8.
18. Dhana A. Diagnosis of cryptococcosis and prevention of cryptococcal meningitis using a novel point-of-care lateral flow assay. Case Rep Med. 2013;2013:1–5.
19. Saha DC, Xess I, Jain N. Evaluation of conventional & serological methods for rapid diagnosis of cryptococcosis. Indian J Med Res. 2008;127(5):483–8.
20. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, Williams GN, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis. 2011;53(10):1019–23.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.